ABBVIE

🇫🇷France

Country: 🇫🇷France

Ownership: -

Established: 2013-01-01

Employees: -

Market Cap: $346B

Website: http://www.abbvie.com

Clinical Trials

Efficacy and Safety of Dalbavancin Compared to Standard of Care Antibiotic Therapy for the Completion of Treatment of Patients With Complicated Bacteremia or Infective Endocarditis

Phase 2

Terminated

Conditions: Endocarditis
Bacteremia

Interventions: Drug: Standard of Care
Drug: Dalbavancin

First Posted Date: 2017-05-11

Last Posted Date: 2022-04-25

Lead Sponsor: AbbVie

Target Recruit Count: 2

Registration Number: NCT03148756

Locations: 🇺🇸
Midway Immunology and Research Center, Fort Pierce, Florida, United States

A Study Evaluating the Safety, Pharmacokinetics and Anti-Tumor Activity of ABBV-176 in Subjects With Advanced Solid Tumors Likely to Express Prolactin Receptor (PRLR)

Phase 1

Terminated

Conditions: Advanced Solid Tumors Cancer

Interventions: Drug: ABBV-176

First Posted Date: 2017-05-09

Last Posted Date: 2018-11-29

Lead Sponsor: AbbVie

Target Recruit Count: 19

Registration Number: NCT03145909

Locations: 🇺🇸
City of Hope /ID# 161079, Duarte, California, United States
🇺🇸
Yale University /ID# 201357, New Haven, Connecticut, United States
🇺🇸
St. Lukes Cancer Institute /ID# 201353, Kansas City, Missouri, United States

and more 8 locations

A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of ABBV-553 in Healthy Volunteers and in Subjects With Psoriasis and Efficacy of ABBV-553 in Subjects With Psoriasis

Phase 1

Terminated

Conditions: Psoriasis

Interventions: Drug: ABBV-553
Drug: Placebo

First Posted Date: 2017-05-09

Last Posted Date: 2017-11-06

Lead Sponsor: AbbVie

Target Recruit Count: 12

Registration Number: NCT03145948

Locations: 🇺🇸
Anaheim Clinical Trials LLC /ID# 164101, Anaheim, California, United States
🇺🇸
Providence Clinical Research /ID# 163867, Toluca, California, United States
🇺🇸
Abbvie Clinical Pharmacology Research Unit /ID# 163866, Grayslake, Illinois, United States

and more 1 locations

SC-004 Alone or With ABBV-181 in Subjects With Epithelial Ovarian, Fallopian Tube, Primary Peritoneal and Endometrial Cancers

Phase 1

Terminated

Conditions: Cancer

Interventions: Drug: SC-004
Drug: ABBV-181

First Posted Date: 2017-05-03

Last Posted Date: 2019-05-14

Lead Sponsor: AbbVie

Target Recruit Count: 24

Registration Number: NCT03138408

Locations: 🇺🇸
Highlands Oncology Group /ID# 209165, Fayetteville, Arkansas, United States
🇺🇸
City of Hope /ID# 202493, Duarte, California, United States
🇺🇸
The Ohio State University - Columbus /ID# 164089, Columbus, Ohio, United States

and more 9 locations

Expanded Access to Glecaprevir/ Pibrentasvir

Conditions: Hepatitis C Virus Infection

First Posted Date: 2017-04-21

Last Posted Date: 2020-01-18

Lead Sponsor: AbbVie

Registration Number: NCT03123965

Locations: 🇸🇮
Univ Medical Ctr Ljubljana /ID# 161419, Ljubljana, Slovenia

Expanded Access to Venetoclax

Conditions: Chronic Lymphocytic Leukemia (CLL)
Multiple Myeloma
Acute Myeloid Leukemia (AML)
Non-Hodgkin's Lymphoma
Acute Lymphoblastic Leukemia (ALL)
Amyloidosis
Plasma Cell Leukemia

First Posted Date: 2017-04-21

Last Posted Date: 2024-04-03

Lead Sponsor: AbbVie

Registration Number: NCT03123029

Expanded Access to ABT-414

Conditions: Glioblastoma or Solid Tumors, Epidermal Growth Factor Receptor (EGFR) Diagnosis

First Posted Date: 2017-04-21

Last Posted Date: 2019-07-15

Lead Sponsor: AbbVie

Registration Number: NCT03123952

Expanded Access to Veliparib

Conditions: Solid Tumors With Documented BRCA, BARD, or PALB or Other Acceptable DNA Mutations or Anomalies That Are Scientifically Sound
Triple Negative Breast Cancer (TNBC)
High Grade Serous Ovarian Cancer
Patients Requiring Veliparib Suspension Formulation

First Posted Date: 2017-04-21

Last Posted Date: 2022-05-24

Lead Sponsor: AbbVie

Registration Number: NCT03123211

A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Moderately to Severely Active Crohn's Disease Who Failed Prior Biologic Treatment

Phase 3

Completed

Conditions: Crohn's Disease

Interventions: Drug: risankizumab SC
Drug: risankizumab IV
Drug: placebo for risankizumab IV

First Posted Date: 2017-04-07

Last Posted Date: 2022-06-14

Lead Sponsor: AbbVie

Target Recruit Count: 618

Registration Number: NCT03104413

Locations: 🇺🇸
TLC Clinical Research Inc /ID# 212501, Los Angeles, California, United States
🇺🇸
Children's Hospital of Pittsburgh of UPMC /ID# 212543, Pittsburgh, Pennsylvania, United States
🇺🇸
Duplicate_Atria Clinical Research /ID# 164504, Little Rock, Arkansas, United States

and more 400 locations

A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Participants With Psoriatic Arthritis Who Have an Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD)

Phase 3

Completed

Conditions: Psoriatic Arthritis

Interventions: Drug: Upadacitinib
Drug: Adalimumab
Drug: Placebo to Upadacitinib
Drug: Placebo to Adalimumab

First Posted Date: 2017-04-07

Last Posted Date: 2024-10-01

Lead Sponsor: AbbVie

Target Recruit Count: 1705

Registration Number: NCT03104400

Locations: 🇺🇸
Great Lakes Clinical Trials /ID# 163435, Chicago, Illinois, United States
🇨🇳
1st Aff Hosp of Bengbu Medical College /ID# 201021, Bengbu, Anhui, China
🇨🇳
The First Affiliated Hospital of Shantou University Medical College /ID# 203371, Shantou, Guangdong, China

and more 342 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy